IZOTROPIC CORP. (1R3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IZOTROPIC CORP. (1R3) has a cash flow conversion efficiency ratio of 0.029x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-157.22K ≈ $-183.81K USD) by net assets (€-5.34 Million ≈ $-6.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See shareholders equity of IZOTROPIC CORP. for net asset value and shareholders' equity analysis.
IZOTROPIC CORP. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
IZOTROPIC CORP. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IZOTROPIC CORP. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YOLO GROUP S.P.A. O.N.
F:X2Y
|
N/A |
|
Satria Antaran Prima Tbk PT
JK:SAPX
|
0.018x |
|
i2S SA
PA:ALI2S
|
0.169x |
|
Sarama Resources Ltd
AU:SRR
|
0.465x |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
0.008x |
|
Irisity AB
ST:IRIS
|
-0.017x |
|
Origin Agritech Ltd
F:39O1
|
N/A |
|
Predilife
PA:ALPRE
|
0.219x |
Annual Cash Flow Conversion Efficiency for IZOTROPIC CORP. (2022–2025)
The table below shows the annual cash flow conversion efficiency of IZOTROPIC CORP. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of IZOTROPIC CORP..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | €-4.86 Million ≈ $-5.68 Million |
€-636.23K ≈ $-743.82K |
0.131x | -15.15% |
| 2024-04-30 | €-3.85 Million ≈ $-4.50 Million |
€-593.57K ≈ $-693.95K |
0.154x | -85.48% |
| 2023-04-30 | €-3.07 Million ≈ $-3.59 Million |
€-3.27 Million ≈ $-3.82 Million |
1.063x | -91.64% |
| 2022-04-30 | €-374.59K ≈ $-437.93K |
€-4.76 Million ≈ $-5.57 Million |
12.718x | -- |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more